1594P SARS-CoV-2 vaccines in cancer patients (pts), real-world data (RWD) from 1069 Belong.life users

Abstract

the vaccination. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast or gynecological cancer. The aim was to improve counseling of our patients in clinical routine.Methods: Since March 15 th 2021, patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate (0-2 days) and late side effects (within two weeks after vaccination). Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to the vaccination were documented. Furthermore, the willingness of non-vaccinated patients to be vaccinated was assessed. The collected data were anonymously analyzed as a part of routine quality assurance.Results: By May 10 th 2021, 111 out of 217 (51.1%) interviewed patients had received at least one shot of COVID-19 vaccine and 21 patients both shots. More than half of the vaccinated patients were >55y (60.2%; mean: 60.7y, range 30-92y); 69% with UICC/ FIGO stage III/IV cancer. 74.6% received Conmirnaty (BioNTech/ Pfizer), 18.9% Vaxzevria (AstraZeneca) and 6.5% Covid-19 Vaccine Moderna. After the first shot, 33.3% of the patients described no side effects, 49.1% reported a local reaction (swelling or pain), 23.4% flu-like symptoms, 10.8% headache and 3.6% nausea. 11 patients had symptoms that lasted longer than two days. In 11 cases, COVID-19 vaccination had an impact on delivery of the systemic therapy (n¼10 postponements of therapy and n¼1 dose reduction). 61.3% of the non-vaccinated patients (in total n¼118) were already registered to get vaccinated; 32.8% chose to postpone vaccination for personal reasons; 5% refused vaccination.Conclusions: Breast and gynecological cancer patients appear to tolerate COVID-19 vaccination well under systemic therapy and only in few cases the vaccination interfered with the treatment schedule. Updated results will be presented at the ESMO Congress.

Frequency and Temporal Evolution of COVID-19 Vaccination Rate Among Oncological Patients Undergoing 18F-FDG-PET

“…To this point, data available on COVID-19 vaccination rate in cancer patients remains sparse with only few studies reporting willingness to receive the vaccine [9][10][11] and even fewer evidence reporting the real world prevalence of vaccination [12]. To our knowledge, our study represents the first description of COVID-19 vaccination rate in cancer patients in Switzerland.…”

Impact of vaccination against COVID-19 on patients with cancer in ACHOC-C19 study: Real world evidence from one Latin American country

“…However, to date, the reports are still scarce and mainly focused on summaries that seem to agree on the effectiveness of vaccines in preventing adverse events if the infection is produced. In contrast to the literature, some have concentrated on characterizing the vaccine-receiving cancer population 22 , 23 , and others have deepened their effectiveness in this vaccinated population 23 , 25 . Below is a description of the most relevant findings, which, without having studied the same outcomes proposed in our research, are to some extent consistent with our conclusion about the effectiveness of vaccines in cancer populations.…”

Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET

“…To this point, data available on COVID-19 vaccination rate in cancer patients remains sparse with only few studies reporting willingness to receive the vaccine [9] , [10] , [11] and even fewer evidence reporting the real world prevalence of vaccination [12] . To our knowledge, our study represents the first description of COVID-19 vaccination rate in cancer patients in Switzerland.…”